0000899243-20-024400.txt : 20200904 0000899243-20-024400.hdr.sgml : 20200904 20200904200029 ACCESSION NUMBER: 0000899243-20-024400 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200701 FILED AS OF DATE: 20200904 DATE AS OF CHANGE: 20200904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weissman James B CENTRAL INDEX KEY: 0001598480 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 201162759 MAIL ADDRESS: STREET 1: C/O DICERNA PHARMACEUTICALS, INC. STREET 2: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-07-01 2020-07-06 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001598480 Weissman James B C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Operating Officer & EVP Common Stock 2020-07-01 4 M 0 4360 2.97 A 26220 D Common Stock 2020-07-01 4 S 0 3053 26.3881 D 23167 D Common Stock 2020-07-01 4 S 0 1307 26.8678 D 21860 D Employee Stock Option (Right to Buy) 2.97 2020-07-01 4 M 0 4360 0.00 D 2027-01-03 Common Stock 4360 25980 D The Reporting Person sold an aggregate of 4,360 shares of common stock on July 1, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.57% of 761,598 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2019. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.705, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.77 to $26.94, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. This amended Form 4 is being filed solely to attach a power of attorney granted by the Reporting Person which was not previously attached. All other information in the original Form 4 remains the same. The original Form 4 was timely filed on July 6, 2020. Exhibit 24 - Power of Attorney /s/ Douglas W. Pagan, attorney-in-fact 2020-09-04 EX-24 2 attachment1.htm EX-24 DOCUMENT
                         LIMITED POWER OF ATTORNEY FOR
                        SECTION 16 REPORTING OBLIGATIONS

     Know all by these presents, that the undersigned hereby makes, constitutes
and appoints each of Douglas Fambrough, Douglas W. Pagan and Tim Bernstein, or
either of them acting individually, and with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:

    (1)  prepare, execute in the undersigned's name and on the undersigned's
         behalf, and submit to the U.S. Securities and Exchange Commission (the
         "SEC") a Form ID, including amendments thereto, and any other documents
         necessary or appropriate to obtain codes and passwords enabling the
         undersigned to make electronic filings with the SEC of reports required
         by Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange
         Act") or any rule or regulation of the SEC;

    (2)  execute for and on behalf of the undersigned, in the
         undersigned's capacity as an officer and/or director of Dicerna
         Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Forms 3,
         4, and 5, including amendments thereto, in accordance with Section
         16(a) of the Exchange Act and the rules and regulations thereunder;

    (3)  seek or obtain, as the undersigned's representative and on the
         undersigned's behalf, information on transactions in the Company's
         securities from any third party, including brokers, employee benefit
         plan administrators and trustees, and the undersigned hereby authorizes
         any such person to release any such information to such attorney-in-
         fact and approves and ratifies any such release of information;

    (4)  do and perform any and all acts for and on behalf of the
         undersigned which may be necessary or desirable to complete and execute
         any such Form 3, 4, or 5, complete and execute any amendment or
         amendments thereto, and timely file such form with the SEC and any
         stock exchange or similar authority; and

    (5)  take any other action of any type whatsoever in connection with
         the foregoing which, in the opinion of such attorney-in-fact, may be of
         benefit to, in the best interest of, or legally required by, the
         undersigned, it being understood that the documents executed by such
         attorney-in-fact on behalf of the undersigned pursuant to this Power of
         Attorney shall be in such form and shall contain such terms and
         conditions as such attorney-in-fact may approve in such attorney-in-
         fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming nor
relieving, nor is the Company assuming nor relieving, any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.  The undersigned
acknowledges that neither the Company nor the foregoing attorneys-in-fact assume
(i) any liability for the undersigned's responsibility to comply with the
requirement of the Exchange Act, (ii) any liability of the undersigned for any
failure to comply with such requirements, or (iii) any obligation or liability
of the undersigned for profit disgorgement under Section 16(b) of the Exchange
Act.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee of
the Company.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 1st day of July, 2020.

                                          /s/ James B. Weissman
                                          --------------------------------------
                                          Signature

                                          James B. Weissman
                                          --------------------------------------
                                          Print Name